DVA logo

DaVita Inc. (DVA)

$173

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on DVA

Market cap

$10.88B

EPS

13.51

P/E ratio

14.7

Price to sales

0.82

Dividend yield

--

Beta

0.871192

Price on DVA

Previous close

$174.22

Today's open

$174

Day's range

$172.78 - $176.69

52 week range

$101 - $247.49

Profile about DVA

CEO

Javier J. Rodriguez

Employees

78000

Headquarters

Denver, CO

Exchange

New York Stock Exchange

Shares outstanding

62900000

Issue type

Common Stock

DVA industries and sectors

Healthcare

Healthcare Providers & Services

News on DVA

DaVita Expands Availability of Advanced Dialysis Therapy to Every U.S. Center

Expanded HD removes a broader range of toxins from the blood, with 95% of patients adopting the therapy within two weeks of nationwide rollout DENVER, Nov. 17, 2026 /PRNewswire/ -- DaVita today announced a major milestone in kidney care: Expanded hemodialysis (Expanded HD) is now available at every DaVita center in the U.S., giving patients nationwide access to an advanced therapy that removes more of the larger toxins, known as middle molecules, that conventional high-flux hemodialysis leaves behind. Within two weeks of the nationwide rollout, physicians have prescribed Expanded HD for 95% of eligible patients, reflecting rapid adoption across communities with different geographies, demographics and resource levels.

news source

PRNewsWire • Nov 17, 2026

news preview

DaVita Expects Fewer Dialysis Treatments in Q4, but Higher Revenue per Visit Could Help Offset the Drop

DaVita NYSE: DVA expects a meaningful sequential decline in dialysis treatments in the fourth quarter because of calendar effects, but higher revenue per treatment should help offset the impact, Chief Financial Officer Joel Ackerman said at the Wolfe Healthcare Conference.

news source

MarketBeat • Nov 13, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. ("DaVita" or the "Company") (NYSE: DVA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

PRNewsWire • Nov 12, 2026

news preview

DVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $DVA--DVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS Law.

news source

Business Wire • Nov 12, 2026

news preview

Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses

Washington Attorney General Nick Brown on Tuesday filed a lawsuit accusing the state's two largest for-profit dialysis providers of imposing illegal noncompete agreements on medical directors, blocking competition and reducing care options for kidney failure patients.

news source

Benzinga • Nov 12, 2026

news preview

DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

news source

Zacks Investment Research • Nov 11, 2026

news preview

DaVita Sees Growth and Drug Savings Offsetting 2027 Reimbursement Pressure

DaVita NYSE: DVA expects stronger dialysis treatment growth and pharmaceutical cost savings to help offset reimbursement pressures in 2027, though Chief Financial Officer Joel Ackerman said changes in patients' insurance coverage will remain a significant headwind.

news source

MarketBeat • Nov 10, 2026

news preview

DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript

DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

DaVita Inc. (DVA) Presents at 2026 UBS Global Healthcare Conference Transcript

DaVita Inc. (DVA) Presents at 2026 UBS Global Healthcare Conference Transcript

news source

Seeking Alpha • Nov 9, 2026

news preview

Lowey Dannenberg, P.C. is Investigating DaVita Inc. (NYSE: DVA) for Potential Violations of the Federal Securities Laws

NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating DaVita Inc. (NYSE: DVA) (“DaVita” or the “Company”) for potential violations of the federal securities laws.

news source

GlobeNewsWire • Nov 9, 2026

news preview

¹ Disclosures

Get started with M1

Invest in DaVita Inc.

Open an M1 investment account to buy and sell DaVita Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in DVA on M1